Effectiveness of hemoperfusion (HP) in hemodialysis (HD) patients with Covid-19 infection.
Transfus Apher Sci
; 61(6): 103589, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-2086790
ABSTRACT
INTRODUCTION:
The aims of this study are to observe the clinical course of all patients affected by infection with SARS-CoV-2 undergoing HD focusing on the impact of HP.METHODS:
Patients were divided into Group A HD sessions with HP and Group B patients without HP. We registered all the data regarding patients' clinical course.RESULTS:
13 patients have been enrolled in group A. 9 patients were discharged from the hospital after 43 days (range 35-56). 30 days was the mean hospitalization stay for the deceased. We did not observe any side effects with HP cartridges. 9 patients did not receive HP during their hospitalization. For those who represented as symptomatic, 8 out of 9 patients died after 6 days of hospitalization (range 1-14), 2 of them in ICU.CONCLUSION:
HP seems to be a helpful, safe and quite efficient tool in the battle against Covid-19 in HD patients.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hemoperfusion
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Transfus Apher Sci
Journal subject:
Hematology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS